How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Current Treatment Options in Neurology

Volumn 19, Issue 1, 2017, Pages

  Horne, Anna Carin ^a   Wickström, Ronny ^a   Jordan, Michael B ^b   Yeh, E Ann ^c   Naqvi, Ahmed ^c   Henter, Jan Inge ^a   Janka, Gritta ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Central nervous system (CNS); Cerebrospinal fluid; Hemophagocytic lymphohistiocytosis (HLH); Intrathecal treatment; Long term effects; Neuroradiology; Overall survival; Treatment

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON ANTIBODY; METHOTREXATE; RUXOLITINIB; THYMOCYTE ANTIBODY;

CASE STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MECHANISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; LUMBAR PUNCTURE; MEDICAL HISTORY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; RETROSPECTIVE STUDY; REVIEW;

EID: 85011394802     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-017-0439-4     Document Type: Review

References (64)

1. • Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81. Since the first classification of histiocytic disorders in 1987, a number of new findings regarding the cellular origins, molecular pathology, and clinical features of histiocytic disorders have been identified. This revised classification system is based on those findings.
2. Meeths M, Horne A, Sabel M, Bryceson YT, Henter JI. Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr Blood Cancer. 2015 Feb;62(2):346–352. doi: 10.1002/pbc.25308
3. Akima M, Sumi SM. Neuropathology of familial erythrophagocytic lymphohistiocytosis: six cases and review of the literature. Hum Pathol. 1984;15:161–8.
4. •• Henter JI, Nennesmo I. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J Pediatr. 1997;130:358–65. In this paper the currently used staging system for the neuropathologic findings in CNS-HLH is presented.
5. Trottestam H, Berglof E, Horne A, et al. Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatr. 2012;101:313–8.
6. Ramachandran B, Balasubramanian S, Abhishek N, Ravikumar KG, Ramanan AV. Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India. Indian Pediatr. 2011;48:31–5.
7. Trottestam H, Horne A, Arico M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577–84.
8. Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology. 2012;78:1150–6.
9. Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997;89:794–800.
10. Yang S, Zhang L, Jia C, Ma H, Henter JI, Shen K. Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2010;54:408–15.
11. •• Jovanovic A, Kuzmanovic M, Kravljanac R, et al. Central nervous system involvement in hemophagocytic lymphohistiocytosis: a single-center experience. Pediatr Neurol. 2014;50:233–7. This single centre experience showed that involvement in HLH is common and is associated with poor outcome, highlightning the imoprtande to monitor and treat CNS-HLH.
12. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21:245–53.
13. •• Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163:1253–9. This review presents the advances in genetic and pathophysiologicl research, rapid diagnostic modalities and clinical managment of HLH.
14. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44:259–72.
15. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.
16. Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2008;140:327–35.
17. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120:e622–8.
18. •• Jackson J, Titman P, Butler S, Bond K, Rao A, Veys P, Chiesa R, Leiper A, Riley L, Gilmour K, et al. Cognitive and psychosocial function post hematopoietic stem cell transplantation in children with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2013;132:889–95.e881–883. This paper presents the first study to have systematically evaluated the cognitive and psychosocial outcomes of HLH survivors. It shows that childhood survivors of HLH are at risk of long-term cognitive and psychosocial difficulties.
19. Kim MM, Yum MS, Choi HW, et al. Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis. Korean J Hematol. 2012;47:273–80.
20. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the international registry. FHL study group of the histiocyte society. Leukemia. 1996;10:197–203.
21. Hirst WJ, Layton DM, Singh S, et al. Haemophagocytic lymphohistiocytosis: experience at two U.K. centres. Br J Haematol. 1994;88:731–9.
22. Koh KN, Im HJ, Chung NG, et al. Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol. 2015;94:51–9.
23. • Dao AT, Luong VT, Nguyen TT, et al. Risk factors for early fatal outcomes among children with hemophagocytic lymphohistiocytosis (HLH): a single-institution case-series in Vietnam. Pediatr Hematol Oncol. 2014;31:271–81. Prospective study of 89 children with HLH from a single center in Vietnam.
24. •• Gratton SM, Powell TR, Theeler BJ, Hawley JS, Amjad FS, Tornatore C. Neurological involvement and characterization in acquired hemophagocytic lymphohistiocytosis in adulthood. J Neurol Sci. 2015;357:136–42. This article is the first report that describes the neurological features of acquired HLH in adults.
25. Feldmann J, Menasche G, Callebaut I, et al. Severe and progressive encephalitis as a presenting manifestation of a novel missense perforin mutation and impaired cytolytic activity. Blood. 2005;105:2658–63.
26. Shinoda J, Murase S, Takenaka K, Sakai N. Isolated central nervous system hemophagocytic lymphohistiocytosis: case report. Neurosurgery. 2005;56:187.
27. Moshous D, Feyen O, Lankisch P, et al. Primary necrotizing lymphocytic central nervous system vasculitis due to perforin deficiency in a four-year-old girl. Arthritis Rheum. 2007;56:995–9.
28. Rostasy K, Kolb R, Pohl D, et al. CNS disease as the main manifestation of hemophagocytic lymphohistiocytosis in two children. Neuropediatrics. 2004;35:45–9.
29. Henter JI, Elinder G. Cerebromeningeal haemophagocytic lymphohistiocytosis. Lancet. 1992;339:104–7.
30. Kieslich M, Vecchi M, Driever PH, Laverda AM, Schwabe D, Jacobi G. Acute encephalopathy as a primary manifestation of haemophagocytic lymphohistiocytosis. Dev Med Child Neurol. 2001;43:555–8.
31. Voeten M, Maes P, Wojciechowski M, Vandenbossche L, Meyts I, Ceulemans B. Extremely elevated cerebrospinal fluid protein levels in a child with neurologic symptoms: beware of haemophagocytic lymphohistiocytosis. Eur J Paediatr Neurol. 2014;18:427–9.
32. Henter JI, Andersson B, Elinder G, Jakobson A, Lubeck PO, Soder O. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1996;27:21–5.
33. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166:95–109.
34. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood. 2013;121:5184–91.
35. Brisse E, Wouters CH, Matthys P. (2016) Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol 174: 203–17.
36. Howells DW, Strobel S, Smith I, Levinsky RJ, Hyland K. Central nervous system involvement in the erythrophagocytic disorders of infancy: the role of cerebrospinal fluid neopterins in their differential diagnosis and clinical management. Pediatr Res. 1990;28:116–9.
37. Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine. 2016;77:227–37.
38. Goo HW, Weon YC. A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis. Pediatr Radiol. 2007;37:1110–7.
39. Ouachee-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117:e743–50.
40. Tateishi Y, Oda S, Sadahiro T, et al. Continuous hemodiafiltration in the treatment of reactive hemophagocytic syndrome refractory to medical therapy. Transfus Apher Sci. 2009;40:33–40.
41. Sparber-Sauer M, Honig M, Schulz AS, et al. Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. Bone Marrow Transplant. 2009;44:333–8.
42. Hu Y, Xu J, Wang L, Li J, Qiu H, Zhang S. Treatment of hemophagocytic lymphohistiocytosis with cyclophosphamide, vincristine, and prednisone. Swiss Med Wkly. 2012;142:w13512.
43. Rajajee S, Ashok I, Manwani N, Rajkumar J, Gowrishankar K, Subbiah E. Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy. Indian J Pediatr. 2014;81:1337–41.
44. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101–9.
45. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367–73.
46. Bonney DK, Htwe EE, Turner A, et al. Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer. 2012;58:459–61.
47. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376–82.
48. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007;29:569–73.
49. Keith MP, Pitchford C, Bernstein WB. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus. J Clin Rheumatol. 2012;18:134–7.
50. • Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014;15:401–8. Retrospective case series of 8 patients in the ICU with secondary HLH. All were treated with anakinra as first line therapy but some also received steroids. Seven out of the eight survived indicating that Anakinra might be initially used for secondary HLH.
51. Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26.
52. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417–9.
53. Hege K, Quigg T, Delgado D. Alemtuzumab, fludarabine, low-dose TBI, and double umbilical cord transplant for primary graft failure in a patient with recurrent HLH. Pediatr Blood Cancer. 2016;63:361–3.
54. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. (2016) Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128: 60–71.
55. Eadie MJ, Brophy TR, Ohlrich G, Tyrer JH. Dexamethasone: pharmacokinetics in neurological patients. Clin Exp Neurol. 1984;20:107–18.
56. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202–7.
57. Ito C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2370–6.
58. McNally JP, Elfers EE, Terrell CE, et al. Eliminating encephalitogenic T cells without undermining protective immunity. J Immunol. 2014;192:73–83.
59. Palmblad K, Schierbeck H, Sundberg E, et al. High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med. 2014;20:538–47.
60. Egorin MJ, Akman SR, Gutierrez PL. Plasma pharmacokinetics and tissue distribution of thiotepa in mice. Cancer Treat Rep. 1984;68:1265–8.
61. Mack F, Baumert BG, Schafer N, et al. Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev. 2016;43:83–91.
62. Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49:736–41.
63. Ruggiero A, Conter V, Milani M, et al. Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs. 2001;3:237–46.
64. Duffner PK, Armstrong FD, Chen L, et al. Neurocognitive and neuroradiologic central nervous system late effects in children treated on pediatric oncology group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the children’s oncology group. J Pediatr Hematol Oncol. 2014;36:8–15.